HRP20150442T1 - Sredstva za izazivanje apoptoze za lijeäśenje raka i imunih i autoimunih bolesti - Google Patents
Sredstva za izazivanje apoptoze za lijeäśenje raka i imunih i autoimunih bolesti Download PDFInfo
- Publication number
- HRP20150442T1 HRP20150442T1 HRP20150442TT HRP20150442T HRP20150442T1 HR P20150442 T1 HRP20150442 T1 HR P20150442T1 HR P20150442T T HRP20150442T T HR P20150442TT HR P20150442 T HRP20150442 T HR P20150442T HR P20150442 T1 HRP20150442 T1 HR P20150442T1
- Authority
- HR
- Croatia
- Prior art keywords
- piperazin
- methyl
- benzamide
- sulfonyl
- chloro
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title claims 3
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- -1 3-nitrophenyl Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 3
- GPPPXKNVTFBSTL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 GPPPXKNVTFBSTL-UHFFFAOYSA-N 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000006491 bone marrow cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000005443 oral cavity cancer Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000002471 spleen cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- FJZOQMFIORMRLP-UHFFFAOYSA-N 2-(benzenesulfonyl)-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)S(=O)(=O)C=2C=CC=CC=2)=C1 FJZOQMFIORMRLP-UHFFFAOYSA-N 0.000 claims 1
- IWWJPGBIUYUWNK-UHFFFAOYSA-N 2-(benzylamino)-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)NCC=2C=CC=CC=2)=C1 IWWJPGBIUYUWNK-UHFFFAOYSA-N 0.000 claims 1
- HXRVIEGQHHOCPR-UHFFFAOYSA-N 2-benzyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)CC=2C=CC=CC=2)=C1 HXRVIEGQHHOCPR-UHFFFAOYSA-N 0.000 claims 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 1
- BNVIHDHSEOBSNQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-isoquinolin-5-ylsulfonylbenzamide Chemical compound C1C(C)(C)CCC(CN2CCN(CC2)C=2C=C(OC=3C=C4C=CNC4=CC=3)C(C(=O)NS(=O)(=O)C=3C4=CC=NC=C4C=CC=3)=CC=2)=C1C1=CC=C(Cl)C=C1 BNVIHDHSEOBSNQ-UHFFFAOYSA-N 0.000 claims 1
- GDQMKMHGQSDLMZ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-naphthalen-2-ylsulfonylbenzamide Chemical compound C1C(C)(C)CCC(CN2CCN(CC2)C=2C=C(OC=3C=C4C=CNC4=CC=3)C(C(=O)NS(=O)(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=C1C1=CC=C(Cl)C=C1 GDQMKMHGQSDLMZ-UHFFFAOYSA-N 0.000 claims 1
- FNICTEPHDSTAQD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-(3-chlorophenyl)sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC(Cl)=C1 FNICTEPHDSTAQD-UHFFFAOYSA-N 0.000 claims 1
- SIJDUBGMHLDPBT-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-(3-cyanophenyl)sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC(C#N)=C1 SIJDUBGMHLDPBT-UHFFFAOYSA-N 0.000 claims 1
- VPXJBJXSVQXVCJ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-(3-fluorophenyl)sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC(F)=C1 VPXJBJXSVQXVCJ-UHFFFAOYSA-N 0.000 claims 1
- CNZAMKRFZAFZPG-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound CN(C)CCOC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 CNZAMKRFZAFZPG-UHFFFAOYSA-N 0.000 claims 1
- DRLIZTXBELGBKR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-methoxy-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound COC1=CC(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 DRLIZTXBELGBKR-UHFFFAOYSA-N 0.000 claims 1
- SRGBCJUILFABMC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(2-chloropyridin-3-yl)sulfonylbenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C(=NC=CC=2)Cl)CC1 SRGBCJUILFABMC-UHFFFAOYSA-N 0.000 claims 1
- JRZLWSQYQUWPCR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(2-oxochromen-6-yl)sulfonylbenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C3C=CC(=O)OC3=CC=2)CC1 JRZLWSQYQUWPCR-UHFFFAOYSA-N 0.000 claims 1
- HCTAJBQMMLMSJI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-fluorophenyl)sulfonyl-2-phenoxybenzamide Chemical compound FC1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=C1 HCTAJBQMMLMSJI-UHFFFAOYSA-N 0.000 claims 1
- SUIJTQPTRDUPEB-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-fluorophenyl)sulfonylbenzamide Chemical compound FC1=CC=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=C1 SUIJTQPTRDUPEB-UHFFFAOYSA-N 0.000 claims 1
- FISAKEDWNVTBGH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonyl-2-phenoxybenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=C1 FISAKEDWNVTBGH-UHFFFAOYSA-N 0.000 claims 1
- KBVMHTSIMLRIFA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonyl-2-phenylmethoxybenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OCC=2C=CC=CC=2)=C1 KBVMHTSIMLRIFA-UHFFFAOYSA-N 0.000 claims 1
- KOJIENBSLDFNMM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonyl-2-phenylsulfanylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)SC=2C=CC=CC=2)=C1 KOJIENBSLDFNMM-UHFFFAOYSA-N 0.000 claims 1
- CQEPWMHPRDDCIE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=C1 CQEPWMHPRDDCIE-UHFFFAOYSA-N 0.000 claims 1
- BXEISNUVXAJJAI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(4-fluorophenyl)sulfonyl-2-phenoxybenzamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 BXEISNUVXAJJAI-UHFFFAOYSA-N 0.000 claims 1
- OWKDGYAQXUCVCU-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(4-fluorophenyl)sulfonylbenzamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1 OWKDGYAQXUCVCU-UHFFFAOYSA-N 0.000 claims 1
- VKQPRWICDULKPK-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(4-hydroxyphenyl)sulfonylbenzamide Chemical compound C1=CC(O)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1 VKQPRWICDULKPK-UHFFFAOYSA-N 0.000 claims 1
- MCSIRHQHADGDEE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(4-nitrophenyl)sulfonyl-2-phenoxybenzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 MCSIRHQHADGDEE-UHFFFAOYSA-N 0.000 claims 1
- MGTVGTCWJPGPAY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(4-nitrophenyl)sulfonylbenzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1 MGTVGTCWJPGPAY-UHFFFAOYSA-N 0.000 claims 1
- CKFOSMPIIUFZEI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[(3-oxo-4h-1,4-benzoxazin-6-yl)sulfonyl]benzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C3NC(=O)COC3=CC=2)CC1 CKFOSMPIIUFZEI-UHFFFAOYSA-N 0.000 claims 1
- XHQMEZQMJATMTR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)sulfonyl]benzamide Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1S(=O)(=O)NC(=O)C(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1C1=CC=C(Cl)C=C1 XHQMEZQMJATMTR-UHFFFAOYSA-N 0.000 claims 1
- ITJFDFILFDAJGH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[5-[ethyl-(2,2,2-trifluoroacetyl)amino]naphthalen-1-yl]sulfonylbenzamide Chemical compound C1=CC=C2C(N(C(=O)C(F)(F)F)CC)=CC=CC2=C1S(=O)(=O)NC(=O)C(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1C1=CC=C(Cl)C=C1 ITJFDFILFDAJGH-UHFFFAOYSA-N 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- DCKVKZZRSYAHLG-UHFFFAOYSA-N n-(3-bromophenyl)sulfonyl-4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(CCCC1)=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(Br)C=CC=2)CC1 DCKVKZZRSYAHLG-UHFFFAOYSA-N 0.000 claims 1
- QMHHGDNHDXXPHX-UHFFFAOYSA-N n-(4-bromophenyl)sulfonyl-4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(CCCC1)=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=CC(Br)=CC=2)CC1 QMHHGDNHDXXPHX-UHFFFAOYSA-N 0.000 claims 1
- MYKWZSCCXSEBGS-UHFFFAOYSA-N n-(4-bromophenyl)sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=CC(Br)=CC=2)CC1 MYKWZSCCXSEBGS-UHFFFAOYSA-N 0.000 claims 1
- XPOXAYYAILGHKP-UHFFFAOYSA-N n-(4-chloro-3-nitrophenyl)sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-phenoxybenzamide Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=C1 XPOXAYYAILGHKP-UHFFFAOYSA-N 0.000 claims 1
- UILCCKJHTVYDMB-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[4-[(4-phenylphenyl)methyl]-3-propan-2-ylpiperazin-1-yl]benzamide Chemical compound CC(C)C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=CC=CC=2)CCN1CC(C=C1)=CC=C1C1=CC=CC=C1 UILCCKJHTVYDMB-UHFFFAOYSA-N 0.000 claims 1
- MOAGJICESAJPLQ-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC=C1 MOAGJICESAJPLQ-UHFFFAOYSA-N 0.000 claims 1
- UWDCQUANIFFSJC-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[4-[[2-(4-chlorophenyl)-6-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)benzamide Chemical compound CN(C)CCOC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC=C1 UWDCQUANIFFSJC-UHFFFAOYSA-N 0.000 claims 1
- UXWMBCNLSPHYRM-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 UXWMBCNLSPHYRM-UHFFFAOYSA-N 0.000 claims 1
- ZTPGNUQTWVCEHN-UHFFFAOYSA-N n-[(6-chloro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-7-yl)sulfonyl]-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C(=CC3=C(S(NC=N3)(=O)=O)C=2)Cl)CC1 ZTPGNUQTWVCEHN-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (4)
1. Spoj ili njegova terapijski prihvatljiva sol, naznačen time, da je spoj odabran iz skupine koja se sastoji od:
- Skupina 1:
4-[4-(3,3-difenilprop-2-enil)piperazin-1-il]-N-[(3-nitrofenil)sulfonil]abenzamid;
N-[(2-bromofenil)sulfonil]-4-(4-{[2-(4-klorofenil)cikloheks-1-en-1-ilimetil}piperazin-1-il)benzamid;
N-[(3-bromofenil)sulfonil]-4-(4-{[2-(4-klorofenil)cikloheks-1-en-1-il]metil}piperazin-1-il)benzamid;
N-[(4-bromofenil)sulfonil]-4-(4-{[2-(4-klorofenil)cikloheks-1-en-1-il]metil}piperazin-1-il)benzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(3-nitrofenil)sulfonil]benzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-(fenilsulfonil)benzamid;
2-(benziloksi)-4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(3-nitrofenil)sulfonil]benzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-N-[(3-nitrofenil)sulfonil]-2-(2-feniletoksi)benzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(3-nitrofenil)sulfonil]-2-fenoksibenzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il-2-fenoksi-N-(fenilsulfonil)benzamid;
N-[(4-bromofenil)sulfonil]-4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}benzamid;
4-[4-(1,1’-bifenil-4-ilmetil)-3-izopropilpiperazin-1-il]-N-(fenilsulfonil)benzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(3-nitrofenil)sulfonil]-2-(feniltio)benzamid;
2-(benzilamino)-4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(3-nitrofenil)sulfonil]benzamid;
2-benzil-4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(3-nitrofenil)sulfonil]benzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(4-nitrofenil)sulfonil]benzamid;
4- {4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(4-hidroksifenil)sulfonil]benzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(3-nitrofenil)sulfonil]-2-(2-feniletil)benzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(4-fluorofenil)sulfonil]benzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(3-fluorofenil)sulfonil]benzamid;
4-{4-[(4,-kloro-1,1,-bifenil-2-il)metil]piperazin-1-il}-N-[(3-nitrofenil)sulfonil]-2-(fenilsulfinyl)benzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(4-nitrofenil)sulfonil]-2-fenoksibenzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(3-fluorofenil)sulfonil]-2-fenoksibenzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(4-fluorofenil)sulfonil]-2-fenoksibenzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-2-metoksi-N-[(3-nitrofenil)sulfonil]benzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(3-nitrofenil)sulfonil]-2-(fenilsulfonil)benzamid;
4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-[(4-kloro-3-nitrofenil)sulfonil]-2-fenoksibenzamid;
4-[4-({4’-kloro-3-[2-(dimetilamino)etoksi]-1,1’-bifenil-2-il}metil)piperazin-1-il]-2-(1H-indol-4-iloksi)-N-[(3-nitrofenil)sulfonil]benzamid; i
4-[4-({4’-kloro-3-[2-(dimetilamino)etoksi]-1,1’-bifenil-2-il}metil)piperazin-1-il]-2-(1H-indol-4-iloksi)-N-(fenilsulfonil)benzamid;
i
- Skupina 2:
4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-indol-5-iloksi)-N-[(3-nitrofenil)sulfonil]benzamid;
4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-indol-5-iloksi)-N-(fenilsulfonil)benzamid;
4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(3-cijanofenil)sulfonil]-2-(1H-indol-5-iloksi)benzamid;
4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(3-klorofenil)sulfonil]-2-(1H-indol-5-iloxy)benzamid;
4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(3-fluorofenil)sulfonil]-2-(1H-indol-5-iloksi)benzamid;
4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-indol-5-iloksi)-N-(2-naftilsulfonil)benzamid;
4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-indol-5-iloksi)-N-(izokinolin-5-ilsulfonil)benzamid;
4-{4-[(4’-klorobifenil-2-il)metil]piperazin-1-il}-N-[(2-kloropiridin-3- il)sulfonil]benzamid;
4-{4-[(4’-klorobifenil-2-il)metil]piperazin-1-il}-N-[(3-oxo-3,4-dihidro-2H-1,4-benzoksazin-6-il)sulfonil]benzamid;
4-{4-[(4’-klorobifenil-2-il)metil]piperazin-1-il}-N-[(6-kloro-1,1-dioksido-2H-1,2,4-benzothiadiazin-7-il)sulfonil]benzamid;
4-{4-[(4’-klorobifenil-2-il)metil]piperazin-1-il}-N-({5-[etil(trifluoroacetil)amino]-1- naftil} sulfonil)benzamid;
4-{4-[(4’-klorobifenil-2-il)metil]piperazin-1-il}-N-[(5,5,8,8-tetrametil-5,6,7,8-tetrahidronaftalen-2-il)sulfonil]benzamid; i
4-{4-[(4’-klorobifenil-2-il)metil]piperazin-1-il}-N-[(2-okso-2H-kromen-6-il)sulfonil]benzamid.
2. Spoj ili terapijski prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time, da j e spoj 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-indol-5-iloksi)-N-[(3-nitrofenil)sulfonil]benzamid.
3. Pripravak za liječenje raka mokraćnog mjehura, raka mozga, raka dojke, raka koštane srži, raka grlića maternice, kronične limfocitne leukemije, raka debelog crijeva, raka jednjaka, raka jetre, limfoblastične leukemije, folikularnih limfoma, limfoidne malignosti T-stanica ili B-stanica, melanoma, mijeloične leukemije, mijeloma, raka usne šupljine, raka jajnika, raka ne-malih plućnih stanica, raka prostate, raka pluća malih stanica ili raka slezene, naznačen time, da navedeni pripravak sadrži pomoćno sredstvo i terapijski učinkovitu količinu spoja ili terapijski prihvatljivu sol prema patentnom zahtjevu 1 ili 2.
4. Spoj ili terapijski prihvatljiva sol u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da se koristi u liječenju raka mokraćnog mjehura, raka mozga, raka dojke, raka koštane srži, raka vrata maternice, kronične limfocitne leukemija, karcinoma debelog crijeva, raka jednjaka, raka jetre, limfoblastične leukemije, folikularnih limfoma, limfoidne malignosti T-stanica ili B-stanica, melanoma, mijelogene leukemije, mijeloma, raka usne šupljine, raka jajnika, raka ne-malih plućnih stanica, raka prostate, raka malih plućnih stanica ili raka slezene kod pacijenta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14562709P | 2009-01-19 | 2009-01-19 | |
| EP12163746.6A EP2511264B1 (en) | 2009-01-19 | 2010-01-15 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150442T1 true HRP20150442T1 (hr) | 2015-05-22 |
Family
ID=42026765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150442TT HRP20150442T1 (hr) | 2009-01-19 | 2015-04-23 | Sredstva za izazivanje apoptoze za lijeäśenje raka i imunih i autoimunih bolesti |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8426422B2 (hr) |
| EP (2) | EP2387560A2 (hr) |
| JP (1) | JP5613176B2 (hr) |
| KR (2) | KR101661126B1 (hr) |
| CN (2) | CN102282129A (hr) |
| AU (1) | AU2010204554B2 (hr) |
| BR (1) | BRPI1006116A2 (hr) |
| CA (2) | CA2747835A1 (hr) |
| DK (1) | DK2511264T3 (hr) |
| ES (1) | ES2536090T3 (hr) |
| HK (1) | HK1177206A1 (hr) |
| HR (1) | HRP20150442T1 (hr) |
| HU (1) | HUE025527T2 (hr) |
| IL (2) | IL213623A (hr) |
| MX (1) | MX2011007681A (hr) |
| NZ (3) | NZ703941A (hr) |
| PL (1) | PL2511264T3 (hr) |
| PT (1) | PT2511264E (hr) |
| RU (1) | RU2539587C2 (hr) |
| SG (2) | SG193849A1 (hr) |
| SI (1) | SI2511264T1 (hr) |
| TW (2) | TWI494303B (hr) |
| WO (1) | WO2010083441A2 (hr) |
| ZA (1) | ZA201104672B (hr) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| LT2982696T (lt) | 2008-11-07 | 2019-06-10 | Amgen Research (Munich) Gmbh | Ūmios limfoblastinės leukemijos gydymas |
| KR101695329B1 (ko) * | 2008-11-07 | 2017-01-23 | 암젠 리서치 (뮌헨) 게엠베하 | 소아 급성 림프구성 백혈병의 치료방법 |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| KR20110116161A (ko) | 2009-01-19 | 2011-10-25 | 아보트 러보러터리즈 | 암, 면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제 |
| AU2010204554B2 (en) * | 2009-01-19 | 2013-05-30 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN109966294A (zh) * | 2009-05-26 | 2019-07-05 | 艾伯维爱尔兰无限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| AU2011229862B2 (en) * | 2010-03-25 | 2014-07-24 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| UA113500C2 (xx) * | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| US20120277210A1 (en) * | 2010-10-29 | 2012-11-01 | Abbott Laboratories | Solid dispersions containing an apoptosis-inducing agent |
| NZ610151A (en) | 2010-11-23 | 2015-06-26 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
| ES2603129T3 (es) | 2010-11-23 | 2017-02-23 | Abbvie Ireland Unlimited Company | Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2 |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| KR20140119023A (ko) | 2011-12-13 | 2014-10-08 | 버크 인스티튜트 포 리서치 온 에이징 | 의료 요법을 개선하는 방법 |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| KR101229430B1 (ko) * | 2012-07-02 | 2013-02-05 | 대한민국 | 〔ｅ〕ｎ〔５〔２〔２〔２，４다이히드록시벤질리덴〕히드라지닐〕２옥소에틸〕１，３，４티아디아졸２일〕４메톡시벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환의 예방 및 치료용 약학적 조성물 |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| EP3293185A1 (en) * | 2013-03-13 | 2018-03-14 | AbbVie Inc. | Processes for the preparation of an apoptosis-inducing agent |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN106163557B (zh) | 2014-01-28 | 2020-07-14 | 巴克老龄化研究所 | 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物 |
| WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| BR112016017997A2 (pt) | 2014-02-03 | 2017-08-08 | Quadriga Biosciences Inc | Beta aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos |
| WO2016010879A1 (en) * | 2014-07-15 | 2016-01-21 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| RU2020134082A (ru) | 2014-10-06 | 2020-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Модуляторы регулятора трансмембранной проводимости при муковисцидозе |
| JP2017537157A (ja) * | 2014-11-27 | 2017-12-14 | アクチュラム・リアル・エステート・アクチエボラーグ | ビス（スルホンアミド）誘導体およびｍＰＧＥＳ阻害薬としてのその使用 |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| EP3331851A1 (en) * | 2015-08-03 | 2018-06-13 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof |
| CN107033043B (zh) * | 2016-02-04 | 2019-04-30 | 中国人民解放军第二军医大学 | N-取代苯磺酰基-取代苯甲酰胺类化合物及其制备药物的用途 |
| PL3436446T3 (pl) | 2016-03-31 | 2023-09-11 | Vertex Pharmaceuticals Incorporated | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa |
| SI3519401T1 (sl) | 2016-09-30 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja |
| CN106565706B (zh) * | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | 一种磺酰胺衍生物及其在药学中的应用 |
| DK3551622T3 (da) | 2016-12-09 | 2020-11-23 | Vertex Pharma | Modulator af transmembrankonduktansregulator af cystisk fibrose, farmaceutiske sammensætninger, behandlingsfremgangsmåder og fremgangsmåde til fremstilling af modulatoren |
| WO2018127130A1 (en) | 2017-01-07 | 2018-07-12 | Shanghai Fochon Pharmaceutical Co., Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| EP3612531B1 (en) * | 2017-04-18 | 2022-08-24 | Shanghai Fochon Pharmaceutical Co., Ltd. | Apoptosis-inducing agents |
| TWI651087B (zh) * | 2017-04-21 | 2019-02-21 | 長庚大學 | 類泛素化抑制劑於預防或治療骨質疏鬆症的用途 |
| EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| AR112467A1 (es) | 2017-08-02 | 2019-10-30 | Vertex Pharma | Procesos para preparar compuestos |
| AU2018351533B2 (en) | 2017-10-19 | 2023-02-02 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EP3788042A4 (en) | 2018-04-29 | 2022-01-26 | BeiGene, Ltd. | BCL-2 INHIBITORS |
| CN109776414B (zh) * | 2019-01-02 | 2022-04-22 | 山东大学 | 一种Bcl-2蛋白抑制剂及其制备方法和应用 |
| US20230128137A1 (en) * | 2020-03-12 | 2023-04-27 | Medshine Discovery Inc. | Benzo five-membered cyclic compound |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| JPH11512429A (ja) | 1995-09-15 | 1999-10-26 | ファルマシア・アンド・アップジョン・カンパニー | アミノアリールオキサゾリジノン ｎ−オキシド |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| EP1351712B1 (en) * | 2000-06-20 | 2007-08-01 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| DK1401806T3 (da) * | 2001-06-06 | 2006-11-27 | Lilly Co Eli | Benzoylsulfonamider og sulfonylbenzamidiner til anvendelse som antitumormidler |
| US20030059489A1 (en) | 2001-09-24 | 2003-03-27 | Canolio Inc. | Genital lubricating compositions and uses thereof |
| AU2003264017B2 (en) | 2002-08-08 | 2010-05-27 | Memory Pharmaceuticals Corporation | Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| US6995787B2 (en) | 2002-08-21 | 2006-02-07 | Adams Steven L | Sports projectile and camera apparatus |
| JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
| AU2004278030C1 (en) | 2003-10-03 | 2010-12-02 | Portola Pharmaceuticals, Inc. | 2,4-Dioxo-3-quinazolinylaryl sulfonylureas |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| DE602004009344T2 (de) | 2004-04-19 | 2008-07-10 | Symed Labs Ltd., Hyderabad | Neues verfahren zur herstellung von linezolid und verwandten verbindungen |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| KR101509440B1 (ko) | 2005-05-12 | 2015-04-07 | 애브비 바하마스 리미티드 | 아폽토시스 촉진제 |
| WO2006127364A1 (en) * | 2005-05-24 | 2006-11-30 | Abbott Laboratories | Apoptosis promoters |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| US7842681B2 (en) * | 2006-09-05 | 2010-11-30 | Abbott Laboratories | Treatment of myeoproliferative diseases |
| KR20090077914A (ko) | 2006-09-11 | 2009-07-16 | 쿠리스 인코퍼레이션 | 항증식제로서의 다작용성 소분자 |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| WO2008064116A2 (en) | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| CA2676944C (en) | 2007-02-15 | 2016-01-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
| BRPI0810362A2 (pt) | 2007-04-19 | 2014-10-29 | Concert Pharmaceuticals Inc | Compostos de morfolinila deuterados |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| WO2009036035A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| WO2009036051A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors containing a zinc binding moiety |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| CN101220008B (zh) * | 2008-01-21 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 化合物abt-263的合成方法 |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| PT2376480T (pt) * | 2008-12-05 | 2016-10-26 | Abbvie Inc | Derivados de sulfonamida como agentes indutores de apoptose seletivos de bcl-2 para o tratamento do cancro e de doenças imunes |
| AU2010204554B2 (en) * | 2009-01-19 | 2013-05-30 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| KR20110116161A (ko) | 2009-01-19 | 2011-10-25 | 아보트 러보러터리즈 | 암, 면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제 |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN109966294A (zh) | 2009-05-26 | 2019-07-05 | 艾伯维爱尔兰无限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| AU2011229862B2 (en) | 2010-03-25 | 2014-07-24 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
-
2010
- 2010-01-15 AU AU2010204554A patent/AU2010204554B2/en not_active Ceased
- 2010-01-15 CN CN2010800047718A patent/CN102282129A/zh active Pending
- 2010-01-15 CA CA2747835A patent/CA2747835A1/en not_active Abandoned
- 2010-01-15 SG SG2013066071A patent/SG193849A1/en unknown
- 2010-01-15 SI SI201030944T patent/SI2511264T1/sl unknown
- 2010-01-15 WO PCT/US2010/021243 patent/WO2010083441A2/en active Application Filing
- 2010-01-15 DK DK12163746.6T patent/DK2511264T3/da active
- 2010-01-15 SG SG2011046836A patent/SG172391A1/en unknown
- 2010-01-15 PT PT121637466T patent/PT2511264E/pt unknown
- 2010-01-15 EP EP10701083A patent/EP2387560A2/en not_active Withdrawn
- 2010-01-15 CN CN201610390761.1A patent/CN106045893A/zh active Pending
- 2010-01-15 ES ES12163746.6T patent/ES2536090T3/es active Active
- 2010-01-15 MX MX2011007681A patent/MX2011007681A/es active IP Right Grant
- 2010-01-15 NZ NZ703941A patent/NZ703941A/en not_active IP Right Cessation
- 2010-01-15 PL PL12163746T patent/PL2511264T3/pl unknown
- 2010-01-15 CA CA2936120A patent/CA2936120A1/en not_active Abandoned
- 2010-01-15 EP EP12163746.6A patent/EP2511264B1/en active Active
- 2010-01-15 RU RU2011134634/04A patent/RU2539587C2/ru not_active IP Right Cessation
- 2010-01-15 HU HUE12163746A patent/HUE025527T2/en unknown
- 2010-01-15 KR KR1020117018581A patent/KR101661126B1/ko active IP Right Grant
- 2010-01-15 BR BRPI1006116A patent/BRPI1006116A2/pt not_active IP Right Cessation
- 2010-01-15 NZ NZ593593A patent/NZ593593A/xx not_active IP Right Cessation
- 2010-01-15 JP JP2011546401A patent/JP5613176B2/ja not_active Expired - Fee Related
- 2010-01-15 NZ NZ61682810A patent/NZ616828A/en not_active IP Right Cessation
- 2010-01-15 KR KR1020167014664A patent/KR20160066014A/ko active IP Right Grant
- 2010-01-18 US US12/689,106 patent/US8426422B2/en not_active Expired - Fee Related
- 2010-01-18 TW TW104101224A patent/TWI494303B/zh not_active IP Right Cessation
- 2010-01-18 TW TW99101256A patent/TWI472527B/zh not_active IP Right Cessation
-
2011
- 2011-06-16 IL IL213623A patent/IL213623A/en not_active IP Right Cessation
- 2011-06-23 ZA ZA2011/04672A patent/ZA201104672B/en unknown
-
2013
- 2013-04-11 HK HK13104411.8A patent/HK1177206A1/xx not_active IP Right Cessation
-
2015
- 2015-04-23 HR HRP20150442TT patent/HRP20150442T1/hr unknown
- 2015-05-04 IL IL238607A patent/IL238607A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150442T1 (hr) | Sredstva za izazivanje apoptoze za lijeäśenje raka i imunih i autoimunih bolesti | |
| RU2497822C2 (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| NZ724602A (en) | Ror-gamma modulators and uses thereof | |
| CA2606783C (en) | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | |
| JP2007519754A5 (hr) | ||
| RU2455288C2 (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| JP2008545686A5 (hr) | ||
| RU2020108515A (ru) | Соединения и способы целевого расщепления андрогенного рецептора | |
| JP2017527578A5 (hr) | ||
| HRP20141094T1 (hr) | 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze | |
| IL295487A (en) | gcn2 modulator compounds | |
| JP2015517981A5 (hr) | ||
| RU2018104868A (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
| NZ598461A (en) | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases | |
| JP2008524244A5 (hr) | ||
| RU2015141713A (ru) | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний | |
| JP2004517080A5 (hr) | ||
| RU2007107189A (ru) | Производные арилпиридина | |
| CA2582029A1 (en) | Aryl nitrogen-containing bicyclic compounds and methods of use | |
| NZ629630A (en) | Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists | |
| JP2011529037A5 (hr) | ||
| EA016687B8 (ru) | Производные циклопропиламида | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| JP2013517273A5 (hr) |